Illumina Inc. and Qiagen N.V. have been on a collision course since 2012. The two are in a race to move next-generation gene sequencing technology beyond big research laboratories and into everyday clinical settings.
Patent litigation in two federal district courts, the Patent Trial and Appeal Board and the U.S. Court of Appeals for the Federal Circuit came to a head Sept. 9 when U.S. District Judge William Alsup of the Northern District of California ordered Netherlands-based Qiagen to stop making and selling its GeneReader product in the United States.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
